CompletedNCT05800860
A Trial of GH001 in Patients With Treatment-resistant Depression
This study evaluated the safety and effectiveness of GH001 for people with depression.
Medication studyAges 18–64Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of GH001 for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Pilsen and 10 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: May 24, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 81
- Sponsor
- GH Research Ireland Limited
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Czechia, Germany, Ireland, ...
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT05800860
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled, Phase 2b Trial With an Open-label Extension to Determine the Safety and Efficacy of GH001 in Patients With Treatment-resistant Depression
Get this study by email
Recruitment & locations
CompletedPilsen, Czechia · Prague, Czechia · Dresden, Germany
9 more locations
- Frankfurt, Germany
- Münster, Germany
- Dublin, Ireland
- Galway, Ireland
- Maastricht, Netherlands
- Gdansk, Poland
- Barcelona, Spain
- Salamanca, Spain
- Czechia
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of GH001 for people with depression.
Who is behind this study?
The study sponsor is GH Research Ireland Limited.
Did this study involve medication?
Yes. The study involved medication, including GH001 and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
